↓ Skip to main content

Dove Medical Press

Article Metrics

Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy

Overview of attention for article published in Clinical Ophthalmology, February 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
4 tweeters
patent
2 patents

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
19 Mendeley
Title
Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
Published in
Clinical Ophthalmology, February 2017
DOI 10.2147/opth.s120162
Pubmed ID
Authors

Arash Maleki, Neerav Lamba, Lina Ma, Stacey Lee, Alexander Schmidt, C Stephen Foster

Abstract

To examine the efficacy of rituximab as a monotherapy or in combination therapy for the treatment of patients with non-paraneoplastic autoimmune retinopathy. Twelve eyes of six patients with non-paraneoplastic autoimmune retinopathy who were treated with rituximab and had at least 6 months of follow-up were included. Demographic data, clinical data, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands were collected from the Massachusetts Eye Research and Surgery Institution database between September 2010 and January 2015. Changes in visual acuity, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands from the initial visit to the most recent visit were examined. From the initial visit to the last visit, visual acuity was stable in eight (66.7%) eyes. Visual field was stable in six (50%) eyes and improved in two (16.7%) eyes. Electroretinography was stable or improved in eight (66.7%) eyes. The average number of anti-retinal and anti-optic nerve antibody bands was reduced. Stabilization and/or improvement of visual acuity, visual field parameters, and electroretinography parameters were observed in a high number of patients (75%) on rituximab, as a monotherapy (one patient) or in combination therapy.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Lecturer > Senior Lecturer 2 11%
Student > Ph. D. Student 2 11%
Student > Postgraduate 2 11%
Professor 1 5%
Unspecified 1 5%
Other 2 11%
Unknown 9 47%
Readers by discipline Count As %
Medicine and Dentistry 4 21%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Nursing and Health Professions 1 5%
Unspecified 1 5%
Economics, Econometrics and Finance 1 5%
Other 1 5%
Unknown 9 47%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2021.
All research outputs
#4,943,827
of 20,833,859 outputs
Outputs from Clinical Ophthalmology
#358
of 2,920 outputs
Outputs of similar age
#77,349
of 282,958 outputs
Outputs of similar age from Clinical Ophthalmology
#10
of 34 outputs
Altmetric has tracked 20,833,859 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,920 research outputs from this source. They receive a mean Attention Score of 4.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,958 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.